Hims & Hers vs Superior Remedies
Two GLP-1 desks, one scoreboard. We put Hims & Hers and Superior Remedies head-to-head on the published Brief Score — the same six factors, scored the same way.
Hims & Hers
FDA warning letter, September 2025 — issued to Hims & Hers Health, Inc. dba Hims. See the FDA's warning letter database.
Superior Remedies
The verdict
Hims & Hers takes this head-to-head.
Hims & Hers scores 85 to 62 on our six-factor Brief Score — Mass-market, app-first weight program with nationwide reach — watch the compounded-supply headlines.
That doesn't make Superior Remedies a bad call — it's best for readers who want a low-dose protocol designed on its own terms rather than a smaller version of a weight-loss plan, and who do not mind starting an eligibility check to learn the price. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Hims & Hers | Superior Remedies | |
|---|---|---|
| Brief Score | 85/100 (B) | 62/100 (C) |
| Semaglutide | $199/mo | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | All 50 states (telehealth nationwide) |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Risingprice rising | Newnew to the tracker, no prior reading |
Hims & Hers: App-first reach is nationwide, but compounded supply has drawn industry-wide scrutiny.
Superior Remedies: New to the tracker on 11 August 2026, read on the provider's own site rather than taken on trust: we loaded https://superiorremedies.com/treatments/glp-1-microdose on 2026-08-11 and it publishes no price and no milligram anywhere on the page. The only figure the public site carries is a homepage headline labeled a limited-time offer, attached to the general pitch rather than to any one of its three programs. There is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Keep comparing
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.